Ventricular Assisted Devices Market to Reach $4.1 Billion, Globally, by 2035 at 8.1% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Ventricular Assist Devices Market By Product (Left Ventricular Assist Devices (LVADs), Right Ventricular Assist Devices (RVADs), and Biventricular Assist Devices (BIVADs)), Application (Bridge-To-Transplant (BTT), Destination Therapy, Bridge-To-Recovery (BTR), and Bridge To Candidacy Therapy), Design (Transcutaneous Ventricular Assist Devices and Implantable Ventricular Assist Devices), and Age (Adults and Pediatrics): Global Opportunity Analysis And Industry Forecast, 2024-2035". According to the report, the global ventricular assisted devices market was valued at $1.6 billion in 2023 and is estimated to reach $4.1 billion by 2035, exhibiting a CAGR of 8.1% from 2023 to 2035.
Rise in adoption of ventricular assisted devices,
advancements in technologies, and presence of key players are factors that
drive the growth of the global ventricular assisted devices market. However,
high cost of devices and procedures is anticipated to hinder the market growth.
Moreover, rise in healthcare expansion is expected to offer remunerative
opportunities for the ventricular assisted devices market during the forecast
period.
𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞
𝐏𝐃𝐅
𝐑𝐞𝐩𝐨𝐫𝐭
𝐰𝐢𝐭𝐡
𝐆𝐫𝐚𝐩𝐡𝐬
𝐚𝐧𝐝
𝐅𝐢𝐠𝐮𝐫𝐞𝐬
𝐇𝐞𝐫𝐞:
https://www.alliedmarketresearch.com/request-sample/2024
Leading Market Players: -
•
Evaheart Inc.
•
Abiomed Inc.
•
Abbott Laboratories
•
CH Biomedical Inc.
•
Carmat SA
•
Bivacor Inc.
•
LivaNova PLC
•
Berlin Heart GmbH
•
Fineheart
•
AdjuCor GmbH
By product, the left ventricular assist devices segment
registered the largest share in 2023, accounting for more than three-fourths of
the global ventricular assisted devices market revenue and is projected to
register the highest CAGR of 8.2% during the forecast period. This increase in
adoption of LVADs is mainly attributed as it is used more commonly than RVADs
for several reasons such as the left ventricle is the main pumping chamber of
the heart and providing support to the left ventricle can have a significant
impact on overall heart function. Furthermore, heart failure is typically
caused by dysfunction in the left ventricle, so LVAD can address the root cause
of the condition. In addition, the availability of LVADs and the preference
over RVAD device owing to their safety and efficacy is further contributing to
the segment growth.
By application, the bridge-to-transplant (BTT) segment
registered the largest share in 2023, accounting for nearly two-fifths of the
global ventricular assisted devices market revenue, owing to rise in awareness
among people regarding bridge-to-transplant therapy, which has significantly
increased the success rate of transplant surgeries.
By design, the implantable ventricular assist devices segment
accounted for the largest share in 2023, accounting for more than 90% of the
global ventricular assisted devices market revenue and is projected to register
highest CAGR of 8.1% during the forecast period owing to the rising prevalence
of epilepsy worldwide and increasing adoption of deep brain stimulation as an
effective treatment option for drug-resistant epilepsy, contributing to the
segment's accelerated growth trajectory.
By age, the adults segment accounted for the largest share in
2023, accounting for more than 90% of the global ventricular assisted devices
market revenue and is projected to register the highest CAGR of 8.2% during the
forecast period owing to technological advancements in the field of VADs and
development of pediatric VADs that are highly efficient in treating heart
failure in pediatric patients.
Region-wise, North America held the highest market share in
terms of revenue in 2023, accounting for nearly half of the global ventricular
assisted devices market revenue. This is primarily attributed to rise in
prevalence of heart failure, high adoption of technologically advanced
ventricular assist devices, developed healthcare infrastructure, and increase
in patient awareness about the availability of treatment options for heart
failure.
However, the Asia-Pacific segment is projected to register the
highest CAGR of 10.7% during the forecast period. This is attributed to the
surge in demand for sophisticated ventricular assist devices, large number of
healthcare reforms, high prevalence of cardiac disorders, and increase in focus
of key players to develop technologically advanced & cost-effective
devices.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞
𝐭𝐡𝐞
𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/purchase-enquiry/2024
Our Market Research Solution Provides You Answer to Below
Mentioned Question:
• Which are the driving factors responsible for the growth
of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow
in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of
revenue, sales and production?
• How far will the market grow in forecast period in terms
of revenue, sales and production?
• Which region is dominating the global market and what are
the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and
how much revenue will these segments account for in 2030?
• Which region has more opportunities?
By Region Outlook
• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Contact Details:
David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market
research and business-consulting wing of Allied Analytics LLP based in
Portland, Oregon. Allied Market Research provides global enterprises as well as
medium and small businesses with unmatched quality of “Market Research Reports”
and “Business Intelligence Solutions.” AMR has a targeted view to provide
business insights and consulting to assist its clients to make strategic
business decisions and achieve sustainable growth in their respective market
domain.
Comments
Post a Comment